Latest News

"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025.

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

As the year comes to a close, we revisit some of this year’s top content on urology coding and reimbursement.

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

In this episode, Timothy Daskivich, MD, joins host Adam Weiner, MD, to discuss survivorship and long-term quality-of-life considerations in prostate cancer care.

The application is supported by results from the phase 3 PIVOT-PO trial.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.

The approval is supported by data from the TRITON3 trial.

Patients with GG1 disease and a high genomic classifier score had a significantly higher risk of disease progression.